PT1789593T - Formas solúveis de glicoproteína g de vírus hendra - Google Patents
Formas solúveis de glicoproteína g de vírus hendraInfo
- Publication number
- PT1789593T PT1789593T PT58575093T PT05857509T PT1789593T PT 1789593 T PT1789593 T PT 1789593T PT 58575093 T PT58575093 T PT 58575093T PT 05857509 T PT05857509 T PT 05857509T PT 1789593 T PT1789593 T PT 1789593T
- Authority
- PT
- Portugal
- Prior art keywords
- glycoprotein
- soluble forms
- hendra virus
- hendra
- virus
- Prior art date
Links
- 102000003886 Glycoproteins Human genes 0.000 title 1
- 108090000288 Glycoproteins Proteins 0.000 title 1
- 241000893570 Hendra henipavirus Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/065—Poxviridae, e.g. avipoxvirus
- C07K14/07—Vaccinia virus; Variola virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18211—Henipavirus, e.g. hendra virus
- C12N2760/18222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18211—Henipavirus, e.g. hendra virus
- C12N2760/18234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18211—Henipavirus, e.g. hendra virus
- C12N2760/18271—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58684304P | 2004-07-09 | 2004-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1789593T true PT1789593T (pt) | 2017-04-24 |
Family
ID=36793510
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT121570717T PT2495252T (pt) | 2004-07-09 | 2005-07-07 | Formas solúveis de glicoproteína g de vírus hendra e de vírus nipah |
PT58575093T PT1789593T (pt) | 2004-07-09 | 2005-07-07 | Formas solúveis de glicoproteína g de vírus hendra |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT121570717T PT2495252T (pt) | 2004-07-09 | 2005-07-07 | Formas solúveis de glicoproteína g de vírus hendra e de vírus nipah |
Country Status (7)
Country | Link |
---|---|
US (7) | US8865171B2 (pt) |
EP (3) | EP2495252B1 (pt) |
AU (2) | AU2005327194B2 (pt) |
ES (2) | ES2622394T3 (pt) |
PT (2) | PT2495252T (pt) |
TR (1) | TR201808440T4 (pt) |
WO (1) | WO2006085979A2 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2495252T (pt) | 2004-07-09 | 2018-06-22 | Henry M Jackson Found Advancement Military Medicine Inc | Formas solúveis de glicoproteína g de vírus hendra e de vírus nipah |
CA2836098C (en) * | 2011-05-13 | 2022-06-21 | Zoetis Llc | Hendra and nipah virus g glycoprotein immunogenic compositions |
WO2012166450A1 (en) * | 2011-05-27 | 2012-12-06 | Merial Limited | Genetic vaccines against hendra virus and nipah virus |
MX2016002903A (es) * | 2013-09-05 | 2016-06-06 | Zoetis Services Llc | Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah. |
JP2017501162A (ja) * | 2013-12-16 | 2017-01-12 | ゾエティス・サービシーズ・エルエルシー | ヘンドラ及びニパウイルスg糖タンパク質免疫原性組成物 |
CN108624602B (zh) * | 2017-03-24 | 2020-10-16 | 华中农业大学 | 一株具有阻断活性的抗尼帕病毒g蛋白的单克隆抗体及其应用 |
JP7370983B2 (ja) | 2017-12-20 | 2023-10-30 | ゾエティス・サービシーズ・エルエルシー | ヘンドラウイルス感染症及びニパウイルス感染症に対するワクチン |
US11890339B2 (en) | 2018-08-03 | 2024-02-06 | The United States of Americam as represented by the Secretary, Department of Health and Human Services | Nipah virus immunogens and their use |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
ES2116269T3 (es) | 1989-03-21 | 1998-07-16 | Vical Inc | Expresion de secuencias exogenas de polinucleotidos en un vertebrado. |
US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
EP0487587A1 (en) | 1989-08-18 | 1992-06-03 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
PT695169E (pt) | 1993-04-22 | 2003-04-30 | Skyepharma Inc | Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao |
ATE304604T1 (de) | 1993-06-24 | 2005-09-15 | Frank L Graham | Adenovirus vektoren für gentherapie |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
EP0716148B1 (en) | 1993-09-15 | 2004-01-02 | Chiron Corporation | Recombinant alphavirus vectors |
BR9407956A (pt) | 1993-10-25 | 1996-11-26 | Canji Inc | Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais |
RU2160093C2 (ru) | 1993-11-16 | 2000-12-10 | Скайефарма Инк. | Везикулы с регулируемым высвобождением активных ингредиентов |
US6436908B1 (en) | 1995-05-30 | 2002-08-20 | Duke University | Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
AU2585395A (en) | 1994-05-09 | 1995-11-29 | Chiron Corporation | Retroviral vectors having a reduced recombination rate |
AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
ATE424463T1 (de) | 1996-05-06 | 2009-03-15 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
US6376471B1 (en) | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
WO2005028673A1 (en) * | 2003-09-22 | 2005-03-31 | Institut Pasteur | A method for detecting nipah virus and method for providing immunoprotection against henipaviruses |
PT2495252T (pt) | 2004-07-09 | 2018-06-22 | Henry M Jackson Found Advancement Military Medicine Inc | Formas solúveis de glicoproteína g de vírus hendra e de vírus nipah |
US7988971B2 (en) * | 2005-03-14 | 2011-08-02 | The United States Of America As Represented By The Department Of Health And Human Services | Human monoclonal antibodies against Hendra and Nipah viruses |
WO2007005244A1 (en) * | 2005-07-05 | 2007-01-11 | The Regents Of The University Of California | Henipavirus receptor and uses thereof |
-
2005
- 2005-07-07 PT PT121570717T patent/PT2495252T/pt unknown
- 2005-07-07 PT PT58575093T patent/PT1789593T/pt unknown
- 2005-07-07 US US11/629,682 patent/US8865171B2/en active Active
- 2005-07-07 EP EP12157071.7A patent/EP2495252B1/en active Active
- 2005-07-07 TR TR2018/08440T patent/TR201808440T4/tr unknown
- 2005-07-07 EP EP05857509.3A patent/EP1789593B1/en active Active
- 2005-07-07 EP EP18160722.7A patent/EP3381930A1/en active Pending
- 2005-07-07 ES ES05857509.3T patent/ES2622394T3/es active Active
- 2005-07-07 ES ES12157071.7T patent/ES2673972T3/es active Active
- 2005-07-07 AU AU2005327194A patent/AU2005327194B2/en active Active
- 2005-07-07 WO PCT/US2005/024022 patent/WO2006085979A2/en active Application Filing
-
2010
- 2010-11-11 AU AU2010241382A patent/AU2010241382B2/en active Active
-
2012
- 2012-06-22 US US13/530,922 patent/US9045532B2/en active Active
- 2012-06-22 US US13/530,866 patent/US9056902B2/en active Active
-
2015
- 2015-04-30 US US14/701,006 patent/US9533038B2/en active Active
-
2016
- 2016-12-30 US US15/395,418 patent/US10053495B2/en active Active
-
2018
- 2018-07-25 US US16/044,985 patent/US20190031719A1/en not_active Abandoned
-
2021
- 2021-01-29 US US17/161,720 patent/US20210230230A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20170174728A1 (en) | 2017-06-22 |
US9056902B2 (en) | 2015-06-16 |
AU2010241382A1 (en) | 2010-12-02 |
AU2005327194B2 (en) | 2010-09-09 |
US20130171131A1 (en) | 2013-07-04 |
US10053495B2 (en) | 2018-08-21 |
AU2005327194A1 (en) | 2006-08-17 |
US20090041772A1 (en) | 2009-02-12 |
EP1789593B1 (en) | 2017-03-15 |
ES2622394T3 (es) | 2017-07-06 |
WO2006085979A2 (en) | 2006-08-17 |
EP2495252A2 (en) | 2012-09-05 |
US20150306208A1 (en) | 2015-10-29 |
EP1789593A2 (en) | 2007-05-30 |
US20190031719A1 (en) | 2019-01-31 |
EP1789593A4 (en) | 2009-12-23 |
EP2495252B1 (en) | 2018-04-18 |
WO2006085979A3 (en) | 2009-04-09 |
EP3381930A1 (en) | 2018-10-03 |
PT2495252T (pt) | 2018-06-22 |
EP2495252A3 (en) | 2013-05-01 |
US9533038B2 (en) | 2017-01-03 |
US8865171B2 (en) | 2014-10-21 |
US20130171132A1 (en) | 2013-07-04 |
ES2673972T3 (es) | 2018-06-26 |
US20210230230A1 (en) | 2021-07-29 |
TR201808440T4 (tr) | 2018-07-23 |
US9045532B2 (en) | 2015-06-02 |
AU2010241382B2 (en) | 2012-10-11 |
WO2006085979A9 (en) | 2009-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200705145B (en) | Rescue of influenza virus | |
IL176486A0 (en) | Azabenzofuran substituted thioureas as inhibtitors of viral replication | |
PL1802579T3 (pl) | Pochodne 3-aryloaminopirydynowe | |
EP1726660A4 (en) | METHOD OF MEASURING GLYCOPROTEINS | |
PL2322516T3 (pl) | Produkty pośrednie do otrzymywania makrocyklicznych inhibitorów wirusa zapalenia wątroby typu C | |
EP1828414A4 (en) | DETECTION OF HUMAN PAPILLOMA VIRUS | |
PT1789593T (pt) | Formas solúveis de glicoproteína g de vírus hendra | |
EP1785131A4 (en) | EXTERNAL PREPARATION OF TYPE S / O | |
AP2006003768A0 (en) | TetraazabenzoÄeÜazulene derivatives and analogs tehereof | |
TWI367257B (en) | Process for the preparation of 2-butanol | |
HK1209752A1 (en) | Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents | |
ZA200702418B (en) | Taste-masking Pharmaceutical compositions | |
ZA200607097B (en) | Processes for the preparation of aryl-and heteroaryl-alkylsulfonyl halides | |
NO20043305D0 (no) | Preparation of lodixanol | |
EP2227483A4 (en) | SOLUBLE FORMS OF HENDRA AND NIPAH VIRUS F-GLYCOPROTEIN AND APPLICATIONS THEREOF | |
EP1802332A4 (en) | MODIFIED HIV-1 CREAM PROTEINS | |
EP1776140A4 (en) | METHOD FOR INHIBITING VIRAL REPLICATION | |
SE0601411L (sv) | Förfarande vid beredning | |
EP1893778A4 (en) | PROOF OF HIV-1 INFECTION | |
ITMI20052464A1 (it) | Procedimento per la preparazi9one di norelgestromin norelgestromina | |
ITMI20041086A1 (it) | Procedimento per la preparazione di idrocarbilalogenuri | |
GB0404518D0 (en) | Protection of sanitaryware | |
AU2004900285A0 (en) | Detection of immunodeficiency viruses | |
ITMI20040368A1 (it) | Processo per la preparazione di drospirenone | |
GB0427190D0 (en) | Chemotherapy of viruses |